Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.04 (overall 0.02) | 0.04 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in choroid plexus epithelial cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7222
Sealed predictions
- ZNF112 in dopamine neurons, braak-0.48 (p 0.195) → +0.29 (p 0.443)receipt 7230
- ZNF112 in oligodendrocytes, braak+0.22 (p 0.567) → +0.36 (p 0.336)receipt 7229
Swarm cases
receipt 7230: ZNF112 in dopamine neurons, braak
- power
- full sample -0.06 (p 0.800, n 18), 95% CI -0.52 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.908, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.07 (p 0.787, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.05, sign flips 4; without severely affected donors -0.06 (p 0.800, n 18). fragile.
- cell type
- strongest in OPCs: -0.63 (p 0.0049, n 18) vs -0.06 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ZNF112 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ZNF112 · OPCs · braak: substantia nigra, an independent cohort (already registered)
receipt 7229: ZNF112 in oligodendrocytes, braak
- power
- full sample +0.18 (p 0.487, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.315, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.35 (p 0.156, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.32, sign flips 0; without severely affected donors +0.18 (p 0.487, n 18). fragile.
- cell type
- strongest in OPCs: -0.63 (p 0.0049, n 18) vs +0.18 in oligodendrocytes. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ZNF112 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ZNF112 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.18 p 0.534 (needs p < 2.9e-4)
Receipts
loading the receipts